GlassScriptPhysician profile
Mark A Lazar
NPI 1710907381
$2,413.19
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $26.73 · 2021: $39.55 · 2022: $123 · 2023: $652 · 2024: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $1,935 · Food and Beverage: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $1,934.72 |
| Food and Beverage | $117.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,400.00 | 2024 | |
| Djo, LLC | $534.72 | 2023 | |
| Sandoz INC. | $69.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $66.48 | 2023 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $52.32 | 2022-2023 | Nuzyra |
| Horizon Therapeutics Plc | $49.28 | 2019-2023 | Krystexxa |
| Organogenesis INC. | $43.00 | 2022 | |
| Smith+Nephew, INC. | $42.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.88 | 2019 | |
| Stryker Corporation | $34.03 | 2019 | |
| Triad Life Sciences INC. | $27.44 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.67 | 2022 | |
| Orthofix Medical, INC. | $18.06 | 2022 | |
| Heron Therapeutics, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.